These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 34010764)

  • 1. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
    Garjani A; Middleton RM; Hunter R; Tuite-Dalton KA; Coles A; Dobson R; Duddy M; Hughes S; Pearson OR; Rog D; Tallantyre EC; das Nair R; Nicholas R; Evangelou N
    Mult Scler Relat Disord; 2021 Jul; 52():102939. PubMed ID: 34010764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
    Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS
    Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.
    Kataria S; Tandon M; Melnic V; Sriwastava S
    eNeurologicalSci; 2020 Dec; 21():100287. PubMed ID: 33163634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia.
    Alshamrani F; Alnajashi H; AlJumah M; Almuaigel M; Almalik Y; Makkawi S; Alsalman S; Almejally M; Qureshi S; Aljarallah S; AlKhawajah N; Kedah H; Alotaibi H; Saeedi J; Alamri A
    Mult Scler Relat Disord; 2021 Jul; 52():103004. PubMed ID: 34049217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis.
    Michelena G; Casas M; Eizaguirre MB; Pita MC; Cohen L; Alonso R; Garcea O; Silva BA
    Mult Scler Relat Disord; 2022 Jan; 57():103368. PubMed ID: 35158474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register.
    Garjani A; Middleton RM; Nicholas R; Evangelou N
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34848503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
    Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
    Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review.
    Jamali E; Shapoori S; Farrokhi MR; Vakili S; Rostamzadeh D; Iravanpour F; Tavakoli Oliaee R; Jafarinia M
    Viral Immunol; 2023; 36(6):368-377. PubMed ID: 37276047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis management during the COVID-19 pandemic.
    Moss BP; Mahajan KR; Bermel RA; Hellisz K; Hua LH; Hudec T; Husak S; McGinley MP; Ontaneda D; Wang Z; Weber M; Tagliani P; Cárdenas-Robledo S; Zabalza A; Arrambide G; Carbonell-Mirabent P; Rodríguez-Barranco M; Sastre-Garriga J; Tintore M; Montalban X; Douglas M; Ogbuokiri E; Aravidis B; Cohen JA; Mowry EM; Fitzgerald KC
    Mult Scler; 2020 Sep; 26(10):1163-1171. PubMed ID: 32772807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
    Kister I; Patskovsky Y; Curtin R; Pei J; Perdomo K; Rimler Z; Voloshyna I; Samanovic MI; Cornelius AR; Velmurugu Y; Nyovanie S; Kim JJ; Tardio E; Bacon TE; Zhovtis Ryerson L; Raut P; Pedotti R; Hawker K; Raposo C; Priest J; Cabatingan M; Winger RC; Mulligan MJ; Krogsgaard M; Silverman GJ
    Ann Neurol; 2022 Jun; 91(6):782-795. PubMed ID: 35289960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.
    Czarnowska A; Kapica-Topczewska K; Zajkowska O; Adamczyk-Sowa M; Kubicka-Bączyk K; Niedziela N; Warmus P; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Nowak K; Bartosik-Psujek H; Lech B; Perenc A; Popiel M; Kucharska-Lipowska M; Chorąży M; Tarasiuk J; Mirończuk A; Kochanowicz J; Lasek-Bal A; Puz P; Maciejowska K; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Zwiernik J; Michałowska A; Nosek K; Zwiernik B; Lewańczyk B; Brola W; Kułakowska A
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
    Barzegar M; Vaheb S; Mirmosayyeb O; Afshari-Safavi A; Nehzat N; Shaygannejad V
    Mult Scler Relat Disord; 2021 Jul; 52():102947. PubMed ID: 33979771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.